At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Jul 16, 2026 at 08:00 ET
Grifols announced first patient dosing in two Phase 3 trials (SIGMA and XPERT) seeking U.S. label expansion for its immunoglobulin products GAMUNEX-C (IVIg) and XEMBIFY (SCIg) into secondary immunodeficiency and CIDP, respectively. The trials are early-stage with no near-term financial impact; the company highlighted XEMBIFY's 60% YoY growth in 2025 as a tailwind for the franchise.
- First patients dosed in two Phase 3 trials: SIGMA (GAMUNEX-C for SID in hematologic cancers) and XPERT (XEMBIFY for CIDP non-inferiority vs GAMUNEX-C).
- XEMBIFY grew nearly 60% year over year in 2025, indicating strong demand for the SCIg product.
- SIGMA targets a population of >1 million U.S. patients with CLL, MM, and NHL; XPERT targets ~60,000 U.S. CIDP patients.
- Both trials are open-label, multicenter studies with small sample sizes (50 and 40 patients respectively).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access